The company said, “Philips reiterates confidence in delivering the plan for 2023-2025, acknowledging that uncertainties remain. For full-year 2024, Philips expects to deliver 3-5% comparable sales growth and an Adjusted EBITA margin of 11-11.5%. The free cash flow from Philips’ businesses is expected to amount to EUR 0.8-1 billion. This only excludes the remaining cash-out related to the previously announced resolution of the economic loss class action in the US. The previously stated 2023-2025 Group financial outlook of mid-single-digit comparable sales growth, low-teens Adjusted EBITA margin, and EUR 1.4-1.6 billion free cash flow now takes the consent decree into account and remains unchanged. It excludes the investigation by the US DOJ related to the Respironics field action and the impact of the ongoing litigation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHG:
- Philips delivers strong full-year results; agrees with FDA on terms of consent decree focused on Philips Respironics in the US
- PHG Earnings this Week: How Will it Perform?
- Settlement administrator reports proposed class settlement in Philips CPAP case
- Philips price target raised to EUR 19 from EUR 18.50 at Morgan Stanley
- Philips completes cancellation of 15.1 million shares
